Recommendations for use of Certican® (everolimus) after heart transplantation: Results from a German and Austrian Consensus Conference

Journal of Heart and Lung Transplantation

Volumn 24, Issue 4 SUPPL., 2005, Pages

  Hummel, Manfred ^a,b  

^a MARTIN LUTHER KRANKENHAUS   (Germany)

^b Paulinenkrankenhaus ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; CYTOCHROME P450 INHIBITOR; ERYTHROMYCIN; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PYRROLE DERIVATIVE; RAPAMYCIN; RIFAMPICIN; STEROID; CYCLOSPORIN; DRUG DERIVATIVE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ARTERIOSCLEROSIS; ARTICLE; BRONCHIOLITIS OBLITERANS; CARDIAC ALLOGRAFT VASCULOPATHY; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DATA ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG POTENCY; DRUG TOLERABILITY; DRUG USE; EXPOSURE; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HEMODYNAMICS; HEMOLYTIC UREMIC SYNDROME; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; LEUKOENCEPHALOPATHY; LEUKOPENIA; LICENSING; LONG TERM CARE; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MICROEMULSION; NEPHROTOXICITY; NEUROPATHY; PHYSICIAN; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; POLYNEUROPATHY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; RISK REDUCTION; SIDE EFFECT; SURGICAL PATIENT; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; AUSTRIA; CONSENSUS DEVELOPMENT; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG COMBINATION; DRUG CONTRAINDICATION; GERMANY; GRAFT REJECTION; REVIEW;

AUSTRIA; CONSENSUS DEVELOPMENT CONFERENCES; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; GERMANY; GLUCOCORTICOIDS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES; SIROLIMUS;

EID: 15044365786     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2005.01.010     Document Type: Article

References (23)

1. S. Vitko, R. Margreiter, W. Weimar Everolimus (Certican®) 12-months safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients Transplantation 78 2004 1532 1540
2. H.J. Eisen, E.M. Tuzcu, R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients N Engl J Med 349 2003 847 858
3. Snell G, Valentine V, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Transplantation (in press).
4. Haverich A, Tuzcu EM, Vigano M, et al. Everolimus in de novo cardiac transplant recipients: 24-month follow-up. ISHLT 23rd annual meeting, April 9-12, 2003, Vienna, Austria (Abstract 207).
5. W. Hauck, D. Delgado, S. Perrone Everolimus reduces cardiac allograft vasculopathy in de novo heart transplant recipients 24 month follow-up (abstract) Can J Cardiol 19 suppl A 2003
6. D. Mancini, M. Vigano, L.A. Pulpon 24-Month results of a multicenter study of Certican® for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients Am J Transplant 3 suppl 5 2003 550
7. Certican® SPC. Summary of product characteristics. Novartis Pharma AG, 2003.
8. E. Minetti, H. Tedesco, J. Pascual Excellent renal function with concentration-controlled everolimus, reduced Neoral exposure and steroids in de novo kidney transplant recipients: 6 months analysis. European Society of Organ Transplantation (ESOT) meeting, Venice 2003 (Abstract/Presentation 248)
9. P. Rigotti, N. Baldan, S. Vitko Excellent graft function in de novo kidney transplant recipients treated with concentration controlled everolimus, reduced Neoral exposure and Simulect: 6 months analysis. European Society of Organ Transplantation (ESOT) meeting, Venice 2003 (Abstract/Presentation 294)
10. J. Dantal, S. Vitko, R. Margreiter Everolimus (Certican®, RAD) is associated with a reduced incidence of CMV infections following renal transplantation. American Transplant Congress, Washington, DC 2002 (Abstract/Presentation 963)
11. P. Vitulo, G.I. Snell, V.G. Valentine One-year results of a multicenter, randomized, double-blind study of everolimus (RAD) vs azathioprine to inhibit the decline of pulmonary function in stable lung transplant recipients. European Society of Organ Transplantation (ESOT) meeting, Venice 2003 (Abstract/Presentation 100)
12. R.C. Starling, J.M. Hareb, P. Hauptmann Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure effect modelling Am J Transplant 4 2004 2126 2131
13. S. Vitko, H. Tedesco, J. Eris Everolimus with optimized cyclosporine dosing in renal transplant recipients 6-month safety and efficacy results of two randomized studies Am J Transplant 4 2004 626 635
14. E. Serrano-Ikkos, B. Lask, B. Whitehead, I. Eisler Incomplete adherence after pediatric heart and heart-lung transplantation J Heart Lung Transplant 17 1998 1177 1183
15. Innofluor Certican® Assay System product insert. Catalog No. 0373290. Seradyn, Inc., Indianapolis, IN.
16. J.M. Kovarik, C.H. Hsu, L. McMahon, S. Berthier, C. Rordorf Population pharmacokinetics of everolimus in de novo renal transplant patients impact of ethnicity and comedications Clin Pharmacol Ther 70 2001 247 254
17. M. Cantarovich, J.G. Besner, J.S. Barkun, E. Elstein, R. Loertscher Two-hour cyclosporine level determination is the appropriate tool in monitoring Neoral therapy Clin Transplant 12 1998 243 249
18. K. Mahalati, P. Belitsky, I. Sketris, K. West, R. Panek Neoral monitoring by simplified sparse sampling area under the concentration-time curve its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation Transplantation 68 1999 55 62
19. M. Cantarovich, E. Elstein, B. de Varennes, J.S. Barkun Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients Transplantation 68 1999 1839 1842
20. D.H. Delgado, V. Rao, R.J. Cusimano Monitoring of cyclosporine 2-hr post-dose and trough levels in heart transplantation J Heart Lung Transplant 21 2002 102 103
21. H. Eisen, H. Ross Optimizing the immunosuppressive regimen in heart transplantation J Heart Lung Transplant 23 suppl 2004 S207 S213
22. J.M. Kovarik, A. Noe, S. Berthier Clinical development of an everolimus pediatric formulation relative bioavailability, food effect, and steady-state pharmacokinetics J Clin Pharmacol 43 2003 141 147
23. B. Nashan Review of the proliferation inhibitor SDZ RAD 001 Expert Opin Investig Drugs 11 2002 1845 1857